Trial · NCT05439902
Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women
NCT05439902, Not applicable, Unknown, Centre Hospitalier Universitaire de Nīmes
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women. Trials, record NCT05439902. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05439902
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women
- NCT number
- NCT05439902
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Conditions
- Multiple Sclerosis, Dysuria, Lower Urinary Tract Symptoms, Voiding Dysfunction, Urinary Retention
- Interventions
- Tamsulosin, Placebo
- First posted
- 2022-06-30
- Last updated
- 2024-06-25
Source ClinicalTrials.gov
Registered outcomes30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Urinary symptoms between groups | Start of first intervention phase (Day 0) | Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35 |
| Primary | Urinary symptoms between groups | End of first intervention phase (Day 30) | Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35 |
| Primary | Urinary symptoms between groups | Start of first intervention phase (Day 60) | Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35 |
| Primary | Urinary symptoms between groups | End of first intervention phase (Day 90) | Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35 |
| Secondary | Urinary symptoms between groups | Start of first intervention phase (Day 0) | Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39 |
| Secondary | Urinary symptoms between groups | End of first intervention phase (Day 30) | Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39 |
| Secondary | Urinary symptoms between groups | Start of first intervention phase (Day 60) | Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39 |
| Secondary | Urinary symptoms between groups | End of first intervention phase (Day 90) | Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39 |
| Secondary | Post-mictional residue between groups | Start of first intervention phase (Day 0) | ml, measured with BladderScan |
| Secondary | Post-mictional residue between groups | End of first intervention phase (Day 30) | ml, measured with BladderScan |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05439902
GET https://conductscience.org/api/trials/v1/NCT05439902/registered?page=2